- Novozymes’ 3Q revenue meets the estimated DKK 4.42 billion, earning DKK 4.46 billion.
- Europe sales increased by 5.6% year over year (y/y) to DKK 1.57 billion.
- North America sales remained steady at DKK 1.47 billion y/y.
- Asia Pacific sales decreased by 4.5% y/y to DKK 805 million.
- Latin America sales increased by 7.5% y/y to DKK 613 million.
- Household care sales rose by 2% y/y to DKK 1.33 billion, beating the estimated DKK 1.26 billion.
- Food and beverage sales slightly increased by 1.8% y/y to DKK 998 million, narrowly missing the estimated DKK 1 billion.
- Bioenergy sales increased by 12% y/y to DKK 1.14 billion, surpassing the estimated DKK 1.06 billion.
- Grain and tech processing sales fell by 13% y/y to DKK 544 million, below the estimated DKK 609.6 million.
- Agriculture and feed sales slightly increased by 1.1% y/y to DKK 449 million, below the estimated DKK 475 million.
- Earnings Before Interest and Taxes (Ebit) was DKK 1.02 billion, less than the estimated DKK 1.06 billion.
- Ebit margin was 22.9%, less than the estimated 23%.
- Earnings Before Interest, Taxes, Depreciation, and Amortization (Ebitda) was DKK 1.35 billion, less than the estimated DKK 1.38 billion.
- Organic revenue increased by 8%, surpassing the estimated 6.11%.
- Net income was DKK 929 million, exceeding the estimated DKK 755.6 million.
- Adjusted Earnings Per Share (EPS) was DKK 3.37, beating the estimated DKK 2.59.
- Novozymes maintains its Ebit margin forecast of 25% to 26%, against an estimate of 23.4%.
- The company also maintains its organic revenue growth forecast of 4% to 6%, against an estimate of 4.73%.
- Novozymes launched four new products in the third quarter.
- CEO Ester Baiget states that with organic sales growth accelerating to 5% after the first nine months, including a strong 8% in the third quarter, the company is on track to meet its full-year guidance.
A look at Novozymes A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Novozymes A/S, a biotechnology based company that researches, develops, produces, and sells enzymes for industrial use, has a long-term outlook that is positive, according to the Smartkarma Smart Scores. The scores, which range from 1 to 5, give the company a score of 2 for value, 3 for dividends, 3 for growth, 3 for resilience, and 3 for momentum.
This indicates that Novozymes A/S has a long-term outlook that is solid, with a good balance between value, dividends, growth, resilience, and momentum. The Company’s presence in the technical enzyme market, the food enzyme market, and the animal feed enzyme market, combined with its worldwide distribution network and sales and service centers, all contribute to the positive long-term outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
